1. Home
  2. MEIP vs AEHL Comparison

MEIP vs AEHL Comparison

Compare MEIP & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • AEHL
  • Stock Information
  • Founded
  • MEIP 2000
  • AEHL 1993
  • Country
  • MEIP United States
  • AEHL China
  • Employees
  • MEIP N/A
  • AEHL N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • AEHL Building Materials
  • Sector
  • MEIP Health Care
  • AEHL Industrials
  • Exchange
  • MEIP Nasdaq
  • AEHL Nasdaq
  • Market Cap
  • MEIP 13.3M
  • AEHL 11.6M
  • IPO Year
  • MEIP 2003
  • AEHL 2007
  • Fundamental
  • Price
  • MEIP $6.60
  • AEHL $4.06
  • Analyst Decision
  • MEIP Hold
  • AEHL
  • Analyst Count
  • MEIP 1
  • AEHL 0
  • Target Price
  • MEIP N/A
  • AEHL N/A
  • AVG Volume (30 Days)
  • MEIP 2.8M
  • AEHL 44.0K
  • Earning Date
  • MEIP 09-18-2025
  • AEHL 05-01-2025
  • Dividend Yield
  • MEIP N/A
  • AEHL N/A
  • EPS Growth
  • MEIP N/A
  • AEHL N/A
  • EPS
  • MEIP N/A
  • AEHL N/A
  • Revenue
  • MEIP N/A
  • AEHL $98,773,000.00
  • Revenue This Year
  • MEIP N/A
  • AEHL N/A
  • Revenue Next Year
  • MEIP N/A
  • AEHL N/A
  • P/E Ratio
  • MEIP N/A
  • AEHL N/A
  • Revenue Growth
  • MEIP 33.76
  • AEHL 36.99
  • 52 Week Low
  • MEIP $1.46
  • AEHL $1.79
  • 52 Week High
  • MEIP $9.00
  • AEHL $193.20
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 81.52
  • AEHL 72.49
  • Support Level
  • MEIP $5.75
  • AEHL $3.53
  • Resistance Level
  • MEIP $9.00
  • AEHL $4.43
  • Average True Range (ATR)
  • MEIP 0.85
  • AEHL 0.32
  • MACD
  • MEIP 0.39
  • AEHL 0.06
  • Stochastic Oscillator
  • MEIP 62.50
  • AEHL 75.63

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About AEHL Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.

Share on Social Networks: